Group 1: Financial Performance - The company reported a total revenue of 464.53 million yuan for 2025, representing a year-on-year increase of 12.43% [1] - The net profit attributable to the parent company was 51.15 million yuan, showing a decline of 1.76% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 23.66 million yuan, significantly increasing compared to 2024 [1] - The growth in performance was primarily driven by overseas revenue, which increased by over 40% and accounted for more than 30% of total revenue [1] - In domestic operations, the usage of pressure monitoring radiofrequency ablation catheters increased by over 70%, contributing to the upgrade of high-end procedures [1] Group 2: Recent Events - The company announced on February 10, 2026, that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter received EU Medical Device Regulation (MDR) certification, facilitating entry into the European market and enhancing its overseas technology matrix [2] - On February 11, 2026, the company disclosed that approximately 346 million shares of restricted stock will be released for trading on March 2, 2026, representing 73.47% of the total share capital, which may exert liquidity pressure on the stock price [2] Group 3: Stock Performance - The stock price experienced fluctuations, closing at 23.50 yuan on February 12, 2026, with a 7-day price change of 0.95% and a volatility of 4.64% [3] - The stock dropped by 1.43% on February 11, 2026, the day the earnings report was disclosed, with a trading volume of 58.88 million yuan [3] - On February 12, 2026, the net outflow of funds from major investors was 5.11 million yuan, while retail investor activity remained high [3] - The medical device sector declined by 0.83% during the same period, underperforming the broader market [3]

Core Viewpoint - The company reported a total revenue of 465 million yuan for the fiscal year 2025, marking a year-on-year increase of 12.43%, while the net profit attributable to the parent company decreased by 1.76% to 51.15 million yuan [1] Group 1: International Expansion - The company has deepened its overseas layout, achieving significant results with overseas revenue growing by over 40% year-on-year, now accounting for more than 30% of total revenue, validating the effectiveness of its international strategy [1] - The high-end pressure monitoring radiofrequency ablation catheter has been commercialized in over 20 countries, and the cryoablation system has successfully obtained EU certification, with commercial applications in Germany, Turkey, Greece, and other countries, receiving positive clinical feedback [1] - The company actively participated in major international academic conferences, showcasing its "electric fire ice" comprehensive solution through high-quality live surgeries and discussions, gaining widespread attention and recognition in the industry [1] Group 2: Domestic Business and Product Innovation - The company continues to focus on breakthroughs in high-end procedures and product innovation, with the volume of three-dimensional surgeries steadily increasing, and the usage of pressure monitoring radiofrequency ablation catheters rising by over 70% year-on-year [2] - The company remains a leader in industry technology, with its self-developed PulseMagic™ TrueForce® disposable pressure monitoring cardiac pulsed electric field ablation catheter approved for market launch in November 2025, becoming the first in China equipped with saline infusion functionality [2] - The collaboration with the affiliated company, Shangyang Medical, which previously received approval for the PulseMagic™ Spiral disposable magnetic electric positioning cardiac pulsed electric field ablation catheter, forms a strong synergy, establishing a complete product matrix in the field of pulsed ablation [2]

Core Insights - The company, Microelectrophysiology, was founded in 2010 with a focus on cardiac electrophysiology, aiming to introduce advanced arrhythmia treatment solutions to China [2] - The company has achieved significant milestones, including the development of the first domestic and third global magnetic positioning three-dimensional cardiac electrophysiology system, breaking the reliance on imports in this field [3] - In 2022, the company was successfully listed on the Sci-Tech Innovation Board, marking a new chapter in its development [3] - The company has established a comprehensive treatment platform integrating "radiofrequency, cryoablation, and pulsed field" technologies, providing a wide range of quality options for clinical applications [3] - The company has expanded its market presence, with products entering numerous core tertiary hospitals in China and being exported to over 30 countries and regions globally [3] Future Outlook - The company plans to continue its strategy of "technological breakthroughs and global development," focusing on the cardiac electrophysiology field and aiming to launch more leading products and solutions [4] - The company is committed to enhancing its global business layout and contributing to the high-quality development of China's medical device industry [4]

Core Insights - The company, founded in 2010, focuses on cardiac electrophysiology, aiming to introduce advanced arrhythmia treatment solutions to China and serve patients effectively [1] - The company has achieved significant milestones, including the development of the first domestic and third global magnetic positioning three-dimensional cardiac electrophysiology system, breaking the reliance on imports in this field [2] - The company went public on the Sci-Tech Innovation Board in 2022, marking a new chapter in its development and emphasizing its commitment to technological innovation [2] Company Development - The company has made substantial investments in research and development, resulting in the successful launch of several high-end products, including a domestic cryoablation system and various catheter technologies [2] - The company has established a comprehensive treatment platform that integrates "radiofrequency, cryo, and pulsed" technologies, providing a wider range of quality options for clinical applications [2] - The company has gained recognition as a high-tech enterprise, with its products widely used in major hospitals across China and exported to over 30 countries and regions globally [2] Future Outlook - The company plans to continue its strategy of "technological breakthroughs and global development," focusing on deepening its presence in the cardiac electrophysiology field and launching more innovative products and solutions [3] - The company aims to enhance its global business layout and contribute to the high-quality development of China's medical device industry [3]

Core Insights - The company achieved a revenue of 224 million yuan in H1 2025, representing a year-over-year increase of 12.80%, and a net profit attributable to shareholders of 32.67 million yuan, up 92.02% year-over-year [1] - In Q2 alone, the company reported a revenue of 120 million yuan, with a year-over-year growth of 9.56%, and a net profit of 14.80 million yuan, reflecting a year-over-year increase of 15.22% [1] Revenue Growth - The company demonstrated steady revenue growth, with significant performance in overseas markets. The core products have seen increasing clinical recognition, particularly in the atrial fibrillation treatment sector [2] - By the end of H1 2025, the company had established a presence in over 1,000 hospitals for three-dimensional electrophysiology surgeries, completing over 80,000 procedures, ranking first among domestic manufacturers [2] - International market revenue grew by over 40% year-over-year in H1 2025, accounting for 31% of total revenue, driven by a focus on core product registrations and deepening distributor channels [2] Profitability and Cost Control - The company achieved a gross margin of 60.10% in H1 2025, an improvement from the previous year, with expectations for sustained high margins as new products are launched [3] - The operating expense ratio remained favorable, with sales expenses at 28.13% (up 0.48 percentage points year-over-year), management expenses at 9.28% (down 0.73 percentage points), and R&D expenses at 13.71% (down 5.71 percentage points), indicating improved operational quality [3] Product Development and Future Growth - The company is among the few globally with a full product line in electrophysiology devices and consumables, continuously increasing R&D investment to ensure long-term growth [3] - A joint venture has successfully launched a pulse ablation product approved by NMPA, enhancing the safety and effectiveness of atrial fibrillation treatments [3] - Ongoing projects include the registration application for pressure pulse catheters and intracardiac ultrasound catheters, with clinical enrollment for RDN products progressing smoothly [3] Future Outlook - The company is positioned as a leading domestic player in the electrophysiology sector, with significant product and technological advantages, expected to benefit from the rapidly expanding market [4] - Revenue forecasts for 2025-2027 have been adjusted to 497 million, 654 million, and 866 million yuan, respectively, with net profit forecasts of 73 million, 121 million, and 183 million yuan [4] - The company is anticipated to maintain a rapid growth trajectory, supported by swift overseas development and gradual domestic product rollout [4]